Preliminary studies have shown that leronlimab treatment of COVID-19 patients induced a reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and resolution of SARS-CoV-2 plasma viremia (112). The gene discussed is IL6; the disease is COVID-19.